Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Don Miller who wrote (3327)	6/21/1999 5:22:00 PM
From: Biomaven	Read Replies (2) \| Respond to of 10280

I think this is actually kind of mixed news for SEPR. From the positive side, it is further validation of SEPR's approach; from the negative side it probably reduces the value of nora slightly as there will no longer be a "built-in" market for it (the people switching from Hismanal will all already be switched to something else by the time nora is approved). J&J obviously wouldn't talk about safety concerns - no need to open themselves up to liability - so it was cast by them as a purely competitive decision. They certainly knew that Hismanal would die anyhow once nora was introduced, and so they made the decision to kill it now (prodded some by the FDA, I would guess). This J&J decision lends credence to the view that their nora decision was simply part of a business strategy to get out of the antihistamine business, not a reflection on nora itself. Peter